Archivos De Bronconeumologia最新文献_第10页

Challenges in the Management of Lung Cancer in ILD ILD 肺癌治疗面临的挑战

IF 8.7 3区医学

Archivos De Bronconeumologia Pub Date : 2024-10-01 DOI: 10.1016/j.arbres.2024.05.013

引用次数: 0

Effect of CPAP Treatment on Cardiovascular Outcomes CPAP 治疗对心血管结果的影响。

IF 8.7 3区医学

Archivos De Bronconeumologia Pub Date : 2024-10-01 DOI: 10.1016/j.arbres.2024.05.029

{"title":"Effect of CPAP Treatment on Cardiovascular Outcomes","authors":"","doi":"10.1016/j.arbres.2024.05.029","DOIUrl":"10.1016/j.arbres.2024.05.029","url":null,"abstract":"<div><h3>Introduction</h3><div>Randomized controlled trials<span><span> (RCT) have not demonstrated a role for continuous positive airway pressure (CPAP) on the secondary prevention of major cardiovascular events in </span>obstructive sleep apnea (OSA) patients. However, participants in RCTs are substantially different from real-world patients. Therefore, we aimed to assess the effect of CPAP treatment on major cardiovascular events in real-world OSA patients.</span></div></div><div><h3>Methods</h3><div>Population-based longitudinal observational study including all OSA patients with an active CPAP prescription at the beginning of 2011 in Catalonia, Spain, that terminated CPAP treatment during 2011 and did not have CPAP prescriptions between 2012-2015; and propensity-score-matched OSA patients that continued CPAP treatment until the end of 2015 or death. Adjusted hazard ratios were used to assess the association between CPAP treatment and overall and cardiovascular mortality, cardiovascular hospitalizations, or major adverse cardiovascular events (MACEs).</div></div><div><h3>Results</h3><div>3638 CPAP terminators and 10,914 propensity-score-matched continuators were included (median age 67 [57–77] years, 71.4% male). During a median follow-up of 47.9 months CPAP continuators showed a lower risk of cardiovascular death than terminators (hazard ratio [HR]: 0.61; 95% confidence interval [CI]: 0.50–0.75) after adjusting by age, sex and key comorbidities. Similar results were found for cardiovascular hospitalizations (HR: 0.87; 95% CI: 0.76–0.99) and MACEs (HR: 0.84; 95% CI: 0.75–0.95).</div></div><div><h3>Conclusion</h3><div>CPAP treatment continuation could be associated with a significantly lower risk of major cardiovascular events in real-world OSA patients. This result highlights the importance of including real-world patients in studies on OSA.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"60 10","pages":"Pages 627-633"},"PeriodicalIF":8.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141320443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Indicators of Exercise Capacity and Respiratory Function in COPD Patients: The Role of Gastrocnemius Muscle Oxygenation and Elastography Levels 慢性阻塞性肺病患者运动能力和呼吸功能的新指标：腓肠肌氧合和弹性成像水平的作用。

IF 8.7 3区医学

Archivos De Bronconeumologia Pub Date : 2024-10-01 DOI: 10.1016/j.arbres.2024.06.001

引用次数: 0

How to Protect Radon Exposed Workers? Advocating for a Specific Health Surveillance Protocol 如何保护接触氡的工人？倡导特定的健康监测协议。

IF 8.7 3区医学

Archivos De Bronconeumologia Pub Date : 2024-10-01 DOI: 10.1016/j.arbres.2024.06.014

引用次数: 0

NRF2 Signaling Pathway in Chemo/Radio/Immuno-Therapy Resistance of Lung Cancer: Looking Beyond the Tip of the Iceberg 肺癌化疗/放疗/免疫治疗耐药性中的 NRF2 信号通路：超越冰山一角

IF 8.7 3区医学

Archivos De Bronconeumologia Pub Date : 2024-10-01 DOI: 10.1016/j.arbres.2024.06.021

Sri Vidya Ramisetti , Tapas Patra , Vinayak Munirathnam , Jyothi Venkat Sainath , Durgadevi Veeraiyan , Akhileshwar Namani

{"title":"NRF2 Signaling Pathway in Chemo/Radio/Immuno-Therapy Resistance of Lung Cancer: Looking Beyond the Tip of the Iceberg","authors":"Sri Vidya Ramisetti , Tapas Patra , Vinayak Munirathnam , Jyothi Venkat Sainath , Durgadevi Veeraiyan , Akhileshwar Namani","doi":"10.1016/j.arbres.2024.06.021","DOIUrl":"10.1016/j.arbres.2024.06.021","url":null,"abstract":"<div><div>Lung cancer is one of the most common causes of cancer death in men and women worldwide. Various combinations of surgery, chemotherapy, radiation therapy and immunotherapy are currently used to treat lung cancer. However, the prognosis remains relatively poor due to the higher frequency of tumor mutational burden (TMB). Nuclear factor E2-related factor 2 (<em>NFE2L2</em>/NRF2) is often considered a primary regulator of the expression of antioxidant enzymes and detoxification proteins and is involved in cytoprotection. On the contrary, NRF2 is even known to induce metastasis and support tumor progression. Kelch-like ECH-associated protein 1 (KEAP1) plays an important role in negatively regulating NRF2 activity <em>via</em> CUL3-mediated ubiquitinylation and successive proteasomal degradation. Extensive research has shown that the genetic alterations of <em>KEAP1</em>/<em>NFE2L2/CUL3</em> genes lead to increased expression of NRF2 and its target genes in lung cancer. Thus, these studies provide ample evidence for the dual role of NRF2 in lung cancer. In this review, we discussed the mechanistic insights into the role of NRF2 signaling in therapy resistance by focusing on cell lines, mouse models, and translational studies in lung cancer. Finally, we highlighted the potential therapeutic strategies targeting NRF2 inhibition, followed by the discussion of biomarkers related to NRF2 activity in lung cancer. Overall, our article exclusively discusses in detail the NRF2 signaling pathway in resistance to therapy, especially immunotherapy, and its therapeutic avenue in the treatment of lung cancer.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"60 ","pages":"Pages S59-S66"},"PeriodicalIF":8.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141690869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-Tuberculous Mycobacterial Pulmonary Disease—Where are we Now? 非结核分枝杆菌肺病--我们现在在哪里？

IF 8.7 3区医学

Archivos De Bronconeumologia Pub Date : 2024-10-01 DOI: 10.1016/j.arbres.2024.07.001

Kartik Kumar , Michael R. Loebinger

引用次数: 0

Tertiary Lymphoid Structure in Tumor Microenvironment and Immunotherapy of Lung Cancer 肿瘤微环境中的三级淋巴结构与肺癌免疫疗法

IF 8.7 3区医学

Archivos De Bronconeumologia Pub Date : 2024-10-01 DOI: 10.1016/j.arbres.2024.07.020

Mei Xie , Xuwen Lin , Xinyu Bao , Yiran Liang , Hui Deng , Jialin Song , Xidong Ma , Xin Zhang , Jie Yao , Lei Pan , Xinying Xue

{"title":"Tertiary Lymphoid Structure in Tumor Microenvironment and Immunotherapy of Lung Cancer","authors":"Mei Xie , Xuwen Lin , Xinyu Bao , Yiran Liang , Hui Deng , Jialin Song , Xidong Ma , Xin Zhang , Jie Yao , Lei Pan , Xinying Xue","doi":"10.1016/j.arbres.2024.07.020","DOIUrl":"10.1016/j.arbres.2024.07.020","url":null,"abstract":"<div><div>Immune checkpoint inhibitors have opened an era of lung cancer therapy. However, a notable disparity exists in the efficacy of immunotherapy among individual patients. The tertiary lymphoid structure (TLS) is an ectopic lymphocyte aggregation that appears under pathological conditions and is the primary site of action for anti-tumor immunity. It is commonly reported that the presence of TLS within the tumor microenvironment (TME) relates to a favorable clinical prognosis and an excellent response to immunotherapy in lung cancer patients. A thorough understanding of TLS and its dynamic changes in TME has become an attractive focus for optimizing immunotherapy strategies for lung cancer. In this review, we comprehensively generalize the composition, formation, mechanism, detection methods of TLS, and summarize the role of TLS in lung cancer immunotherapy. Finally, induction of TLS is also discussed, which may provide more effective therapeutic strategies for lung cancer therapy.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"60 ","pages":"Pages S77-S85"},"PeriodicalIF":8.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141851488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex-specific Difference for Small Cell Lung Cancer from Immunotherapy Advancement 免疫疗法的发展对小细胞肺癌的性别差异。

IF 8.7 3区医学

Archivos De Bronconeumologia Pub Date : 2024-10-01 DOI: 10.1016/j.arbres.2024.05.025

{"title":"Sex-specific Difference for Small Cell Lung Cancer from Immunotherapy Advancement","authors":"","doi":"10.1016/j.arbres.2024.05.025","DOIUrl":"10.1016/j.arbres.2024.05.025","url":null,"abstract":"<div><h3>Background</h3><div>The treatment of lung cancer has witnessed significant progress, leading to improved survival rates among patients. It is important to assess the individual contributions of non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) to overall lung-cancer incidence and mortality trends based population, especially sex difference.</div></div><div><h3>Methods</h3><div>We analyzed lung cancer mortality based on subtype, gender, and calendar year. The Joinpoint software was used to identify any changes in incidence and trends in mortality.</div></div><div><h3>Results</h3><div>Incidence and incidence-based mortality declined from 2001 to 2019 both NSCLC and SCLC annually. The most significant decrease occurred between 2016 and 2019 with annual percent change of 5.71%. From 2012 to 2016, the incidence-based mortality of SCLC in women changed by 2.7% in tandem with incidence decreased 2.84%. Remarkably, the incidence-based mortality for women declined notably by 5.23% between 2016 and 2019, even as the incidence showed a less extent of decreasing (-2.59%). The survival rate for women was 15.2% in 2001, 19.3% in 2016, it had increased to 21.3% in 2018 but similar trends not in men. The survival curve showed the change in survival outcomes over time among men and women (median overall survival: 13 vs 23months) receiving immunotherapy for SCLC.</div></div><div><h3>Conclusion</h3><div>Population-level mortality from NSCLC and SCLC in the United States fell sharply from 2016 to 2019 as incidence deceased, and survival improved substantially. Our analysis suggests that approval for and use of immunotherapy may explain the mortality reduction observed during this period, with significant benefits especially for SCLC patient in women.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"60 ","pages":"Pages S13-S21"},"PeriodicalIF":8.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sleep Quality in Patients Receiving Long-term NIV: A Prospective Cohort Study 长期 NIV 患者的睡眠质量：前瞻性队列研究

IF 8.7 3区医学

Archivos De Bronconeumologia Pub Date : 2024-10-01 DOI: 10.1016/j.arbres.2024.05.030

引用次数: 0

Radiomics and Clinical Data for the Diagnosis of Incidental Pulmonary Nodules and Lung Cancer Screening: Radiolung Integrative Predictive Model 用于诊断偶发肺结节和肺癌筛查的放射组学和临床数据：放射肺综合预测模型。

IF 8.7 3区医学

Archivos De Bronconeumologia Pub Date : 2024-10-01 DOI: 10.1016/j.arbres.2024.05.027

{"title":"Radiomics and Clinical Data for the Diagnosis of Incidental Pulmonary Nodules and Lung Cancer Screening: Radiolung Integrative Predictive Model","authors":"","doi":"10.1016/j.arbres.2024.05.027","DOIUrl":"10.1016/j.arbres.2024.05.027","url":null,"abstract":"<div><h3>Introduction</h3><div><span><span>Early diagnosis of lung cancer (LC) is crucial to improve survival rates<span>. Radiomics models hold promise for enhancing LC diagnosis. This study assesses the impact of integrating a clinical and a radiomic model based on deep learning to predict the </span></span>malignancy of </span>pulmonary nodules (PN).</div></div><div><h3>Methodology</h3><div><span>Prospective cross-sectional study of 97 PNs from 93 patients. Clinical data included epidemiological risk factors and pulmonary function tests. The region of interest of each chest CT containing the PN was analysed. The radiomic model employed a pre-trained convolutional network to extract visual features. From these features, 500 with a positive standard deviation were chosen as inputs for an optimised neural network. The clinical model was estimated by a </span>logistic regression model using clinical data. The malignancy probability from the clinical model was used as the best estimate of the pre-test probability of disease to update the malignancy probability of the radiomic model using a nomogram for Bayes’ theorem.</div></div><div><h3>Results</h3><div>The radiomic model had a positive predictive value (PPV) of 86%, an accuracy of 79% and an AUC of 0.67. The clinical model identified DLCO<span>, obstruction index and smoking status as the most consistent clinical predictors associated with outcome. Integrating the clinical features into the deep-learning radiomic model achieves a PPV of 94%, an accuracy of 76% and an AUC of 0.80.</span></div></div><div><h3>Conclusions</h3><div>Incorporating clinical data into a deep-learning radiomic model improved PN malignancy assessment, boosting predictive performance. This study supports the potential of combined image-based and clinical features to improve LC diagnosis.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"60 ","pages":"Pages S22-S30"},"PeriodicalIF":8.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141320391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0